Adding ICIs to Percutaneous Hepatic Perfusion Improves Survival in Metastatic Uveal Melanoma In this phase 2 study, researchers aimed to evaluate the efficacy and safety of combining percutaneous hepatic perfusion with ipilimumab and nivolumab.

Adding the ICIs ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with metastatic #uvealMelanoma. Published by @thelancetoncol.bsky.social.

https://bit.ly/4bp5Vsf

#melanoma #melsm

The ORR was 28.2% for younger patients and 30.4% for older patients, and the DCR was 43.9% and 48.8%, respectively.

https://bit.ly/4smejPS

#melanoma #melsm #skcsm

Percutaneous Hepatic Perfusion Could Boost Immunotherapy Response in Metastatic Melanoma | OncLive Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Percutaneous Hepatic Perfusion Could Boost Immunotherapy Response in Metastatic Melanoma @vincentmamd.bsky.social #melsm #oncology
www.onclive.com/view/percuta...

Skin Fluorescence Imaging Accurately Flags High-Risk Melanocytic Lesions - Oncology Nurse Advisor This prospective validation study explored the sensitivity and specificity of skin fluorescent imaging in distinguishing high vs low risk melanocytic lesions.

Skin fluorescent imaging demonstrated high sensitivity and specificity for distinguishing low-risk from high-risk #melanocyticLesions.

https://bit.ly/466Q6oh

#melsm

What is an overused oncology buzzword❓Experts at #Tandem26 weighed in with their own hot takes. 🤔

@astct.bsky.social @cibmtr.bsky.social #lymsm #leusm #melsm #oncology #hematology #AI

Check out the video here ➡️: www.onclive.com/shorts/overu...

Watch 👀: Amrita Desai, MD, MPH of @ohsunews.bsky.social discusses lifileucel in metastatic melanoma at #Tandem26.

#melsm #oncology @astct.bsky.social @cibmtr.bsky.social

See the whole video here ➡️: onclive.com/shorts/tackl...

Thank you to Dr Amrita Desai, of @ohsunews.bsky.social, for stopping by during #Tandem26 to chat about real-world outcomes with lifileucel in melanoma! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #melsm
www.onclive.com/conference/tct

PD-L1/IDO1–Targeted Vaccine Therapy Is Safe and Effective in Advanced Melanoma | OncLive Jessica C. Hassel, MD, discusses the mechanism of action of the IO102-IO103 vaccine and the implications of efficacy data with this vaccine in melanoma.

PD-L1/IDO1–Targeted Vaccine Therapy Is Safe and Effective in Advanced Melanoma
#melsm #oncology
www.onclive.com/view/pd-l1-i...

Pembrolizumab Associated With Durable Long-Term Survival in Previously Treated Melanoma In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

In previously treated patients with #melanoma, pembrolizumab therapy is associated with durable long-term survival.

https://bit.ly/3YOgS0p

#melsm

AI-Detected Tumor-Infiltrating Lymphocytes Associated with ICI Response in Melanoma “These findings support the potential of AI-driven histopathological analysis as a biomarker in melanoma,” study researchers wrote.

In #melanoma patients, the presence of TILs in pretreatment samples, detected using an #AI-based tool, is associated with outcomes with ICI therapy. Published in @jamaoncology.com.

https://bit.ly/43uCx0C

#melsm

Metastatic Melanoma Survival Worse in Hispanic Patients Than Non-Hispanic Patients In this study, researchers explored disparities in metastatic cutaneous melanoma survival following the introduction of immunotherapies.

Hispanic patients with metastatic cutaneous #melanoma have worse survival outcomes than non-Hispanic patients.

https://bit.ly/48Q2D0Y

#melsm

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma | OncLive AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma @myesmo.bsky.social #ESMO25 #oncology #melsm www.onclive.com/view/amt-253...

AI-Detected Tumor-Infiltrating Lymphocytes Associated with ICI Response in Melanoma “These findings support the potential of AI-driven histopathological analysis as a biomarker in melanoma,” study researchers wrote.

In #melanoma patients, the presence of tumor-infiltrating lymphocytes in pretreatment samples, detected using an AI-based tool, is associated with outcomes with ICI therapy. Published in @jamaoncology.com.

https://bit.ly/43uCx0C

#melsm #skcsm

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma | OncLive EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma @myesmo.bsky.social #melsm #ESMO25 www.onclive.com/view/evx-01-...

NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma | OncLive Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.

NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma @myesmo.bsky.social #ESMO25 #ESMO2025 #melsm #oncology
www.onclive.com/view/nadina-...

Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, according to research presented at #ESMO25 by Dr Jacob Orme of @mayocliniccancer.bsky.social. #melsm #skcsm #ESMO25

shorturl.at/t5NSs

The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, has shown durable activity in patients with advanced melanoma, according to research presented #ESMO25 by Dr Adnan Khattak. #melsm #skcsm #esmo2025

shorturl.at/Yl08y

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma | OncLive Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma #ESMO25 #melsm #oncology www.onclive.com/view/pembrol...

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma | OncLive Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma @myesmo.bsky.social #ESMO25 #ESMO2025 #melsm #oncology
www.onclive.com/view/adjuvan...

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy | OncLive WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy @fda.gov #melsm #oncology
www.onclive.com/view/wtx-124...

Neoadjuvant Daromun Yields Improved Recurrence-Free Survival in Locally Advanced Melanoma | OncLive Significantly longer recurrence-free survival has been demonstrated with neoadjuvant daromun vs surgery alone in patients with locally advanced melanoma.

Neoadjuvant Daromun Yields Improved Recurrence-Free Survival in Locally Advanced Melanoma
#melanoma #melsm
www.onclive.com/view/neoadju...

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma | OncLive Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social #IMS2025 #melsm
www.onclive.com/view/isa-krd...

Adding Lenvatinib to Pembrolizumab Provides No Benefit in Unresectable Melanoma “Immunotherapy remains the standard of care for the first-line treatment of advanced melanoma,” the researchers wrote.

Adding lenvatinib to treatment with pembrolizumab does not improve outcomes in patients with unresectable, advanced melanoma who have not received prior treatment with PD-(L)1 inhibitors, research suggests. shorturl.at/4fVxp #skcsm #melsm

Cancer Vaccine Candidate Narrowly Misses Endpoint in Advanced Melanoma Trial - Oncology Nurse Advisor Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 positive cells.

Topline results were announced from a phase 3 trial evaluating Cylembio® (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced #melanoma. From @medicalprofref.bsky.social.

https://bit.ly/4g34JMY

#melsm #skcsm

FDA Grants Type A Meeting to Discuss RP1 Plus Nivolumab in Advanced Melanoma The FDA scheduled a Type A meeting with the developer of RP1 to discuss the CRL that was granted to RP1 plus nivolumab for advanced melanoma.

FDA Grants Type A Meeting to Discuss RP1 Plus Nivolumab in Advanced Melanoma
@fda.gov #Melanoma #melsm
www.onclive.com/view/fda-gra...

Outcomes of Extending ET, Single Agents Show Promise, and More This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Recent studies highlight the effects of extending ET in postmenopausal women with ER+ early breast cancer, suggest that dacomitinib exhibits intracranial activity in patients with NSCLC and brain metastases, and more. shorturl.at/RaYOz #bcsm #lcsm #melsm #hncsm #lymsm #mmsm #OncSky

New Cancer Treatments That Improve Survival May Also Worsen Disparities “he introduction of effective cancer innovations increased population-level health among patients with advanced lung cancer and melanoma but also widened the survival gap across county-level income gr...

Recent treatment innovations for lung cancer and #melanoma have improved survival overall, but also increased #disparities in survival according to income, researchers report. shorturl.at/UefmZ #lcsm #melsm #OncSky

Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC #melsm #kcsm #oncology www.onclive.com/view/nemvale...

Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma
@moffittnews.bsky.social #melsm #Melanoma
www.onclive.com/view/neoadju...

High Sucralose Intake May Reduce Efficacy of ICIs “Future prospective studies will be necessary to assess potential causation of sucralose in driving immunotherapy resistance as well as to determine how other demographic factors, including location a...

High intake of the artificial sweetener sucralose may reduce the efficacy of immune checkpoint inhibitors in cancer patients, according to research published in @aacrjournals.bsky.social. shorturl.at/U9TvO #lcsm #skcsm #melsm #OncSky